醒脑静注射液对急性脑缺血大鼠炎症反应及病理的影响  

Effect of Xingnaojing injection on inflammatory reaction and brain edema and preparations in rats with acute brain ischemia

作　　者：吴玉生[1] 张文高[2] 郑国玲[1] 张剑[1] 

机构地区：[1]山东大学西区医院内科,山东济南250012 [2]山东中医药大学基础医学院内科教学研究中心,山东济南250014

出　　处：《山东大学学报（医学版）》2007年第7期746-748,共3页Journal of Shandong University:Health Sciences

摘　　要：目的:探讨醒脑静注射液对大鼠急性脑缺血损伤的保护作用。方法:75只大鼠随机分为模型组、对照组、醒脑静组,每组25只,模型组与对照组腹腔注射生理盐水(4 ml/Kg.体重),醒脑静组腹腔注射醒脑静注射液(4 ml/Kg.体重),均为每天2次,共5 d。然后对模型组及醒脑静组大鼠采用结扎双侧颈总动脉法造成急性脑缺血模型,术后药物剂量加倍注射1次。观察三组大鼠血清肿瘤坏死因子-a(TNF-α)、细胞间粘附分子-1(ICAM-1)水平、脑含水量、脑组织病理形态。结果:模型组大鼠血清TNF-α、ICAM-1水平、脑含水量显著高于醒脑静组和对照组(P均<0.01);光镜下观察大鼠脑组织病理形态可见,模型组损伤最明显,醒脑静组次之,对照组损伤不明显。相关分析表明,血清TNF-α水平与ICAM-1水平呈正相关性(P<0.01);血清TNF-α、ICAM-1水平与脑含水量呈正相关性(P<0.01)。结论:醒脑静注射液可抑制炎症反应、减轻脑水肿程度、减轻病理损伤,提示醒脑静注射液对脑缺血有一定的保护作用。Objective： To explore the protection of Xingnaojing injection（XI） on rats with acute brain ischemia. Methods： Seventy-five rats were randomly divided into three groups（ 25 in each）. The control and model groups were subjected to 0.9% Nacl（4 ml/Kg）and the XI group was subjected to XI （4 ml/Kg） through the abdominal cavity, twice a day for 5 days. Then the two sides, of the general carotids of the model and XI groups were tied-up to cause acute brain isehemia. After the operations, they were subjected to double dosages. Serum tumor necrosis factor-α（TNF-α）, intercellular adhension molecule-1 （ICAM-1） levels, brain edema and preparations were determined. Results： Serum TNF- α, ICAM-1 levels and brain edema of the model group were higher than those of the control and XI groups（ P 〈 0.01）. The injury degree of preparations of the model group was heavier than that of the XI group. There were positive correlations between TNF-α and ICAM-I（ P 〈 0.01）, between TNF-α and brain edema（ P 〈 0.01）, and between ICAM-1 and brain edema（ P 〈 0.01. Conclusion： XI could inhibit the inflammatory reaction and decrease brain edema, and protect the acute brain isehemia of rats.

关 键 词：醒脑静注射液 脑缺血 肿瘤坏死因子-A 细胞间粘附分子-1 脑含水量 病理 大鼠 Wistar 

分 类 号：R743.3[医药卫生—神经病学与精神病学] R-332[医药卫生—临床医学]